Abstract
The term Raynaud's phenomenon describes an abnormal vasospastic response to cold or emotional stress. It is a common condition with a prevalence of 3-5% of the population. Clinically, Raynaud's phenomenon manifests as sharply demarcated colour changes of the skin of the digits that is often accompanied by paraesthesia. Raynaud's phenomenon can be subdivided into primary, or idiopathic, and secondary forms, in the latter of which associated diseases or causes can be identified. The pathogenesis of the disease is incompletely understood. Pathologic changes have been observed primarily in vascular smooth muscle cells, endothelial cells and perineuronal microvasculature. Current therapeutic strategies include supportive treatments, topical therapeutic approaches and systemic medication. Drug therapies with proven efficacy include calcium channel blockers, prostacyclin analogues, fluoxetine, losartan and sildenafil.
MeSH terms
-
Angiotensin II Type 1 Receptor Blockers / adverse effects
-
Angiotensin II Type 1 Receptor Blockers / therapeutic use
-
Angiotensin-Converting Enzyme Inhibitors / adverse effects
-
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
-
Calcium Channel Blockers / adverse effects
-
Calcium Channel Blockers / therapeutic use
-
Combined Modality Therapy
-
Endothelium, Vascular / pathology
-
Humans
-
Life Style
-
Muscle, Smooth, Vascular / pathology
-
Phosphodiesterase Inhibitors / adverse effects
-
Phosphodiesterase Inhibitors / therapeutic use
-
Prostaglandins I / therapeutic use
-
Raynaud Disease / diagnosis*
-
Raynaud Disease / etiology*
-
Raynaud Disease / pathology
-
Raynaud Disease / therapy
-
Risk Factors
-
Selective Serotonin Reuptake Inhibitors / adverse effects
-
Selective Serotonin Reuptake Inhibitors / therapeutic use
-
Serotonin Antagonists / adverse effects
-
Serotonin Antagonists / therapeutic use
Substances
-
Angiotensin II Type 1 Receptor Blockers
-
Angiotensin-Converting Enzyme Inhibitors
-
Calcium Channel Blockers
-
Phosphodiesterase Inhibitors
-
Prostaglandins I
-
Serotonin Antagonists
-
Serotonin Uptake Inhibitors